Clinical trials recruiting for Melanoma Stage III
18
Recruiting trials
17
US states with sites
9
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nivolumab | 5 |
| Binimetinib | 2 |
| Cyclophosphamide | 2 |
| Ipilimumab | 2 |
| Pembrolizumab | 2 |
| ADP-TILIL7 | 1 |
| Binimetinib Pill | 1 |
| Encorafenib | 1 |
| Encorafenib Pill | 1 |
| Fludarabine Phosphate | 1 |
| Imatinib | 1 |
| Interleukin-2 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 5 |
| California | 4 |
| Kentucky | 2 |
| Nebraska | 2 |
| New York | 2 |
| Pennsylvania | 2 |
| Wisconsin | 2 |
| Connecticut | 1 |
| Indiana | 1 |
| Iowa | 1 |
| Michigan | 1 |
| Minnesota | 1 |
Top cities
Tampa, Florida 3Madison, Wisconsin 2New York, New York 2Omaha, Nebraska 2Orange, California 2Pittsburgh, Pennsylvania 2Canton, Ohio 1Cleveland, Ohio 1Detroit, Michigan 1El Paso, Texas 1
Self-screener
Recruiting trials
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
- Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
- Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
- Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
- Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
- FMT to Convert Response to Immunotherapy
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
- Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
- The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
- Versatile Ampification Single-Molecule Detection in Liquid Biopsy
Related conditions
Trials recruiting for Melanoma Stage III often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Melanoma Stage IV 23Melanoma (Skin) 18Unresectable Melanoma 11Pediatric ALL 4Metastatic Melanoma 40Liquid Biopsy 6Immunotherapy 40Cutaneous Melanoma 27BRAF V600 Mutation 4
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Melanoma Stage III trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.